Cambium Biomaterials, Inc.
Classification
Private
Financials
Revenue & Profit
Valuation
Ratios
People
Deals
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
Funding
About
About
Cambium Biomaterials, Inc. is a privately-held developer of an advanced materials platform that combines AI-driven molecular design with state-of-the-art chemistry, materials science, biology, and manufacturing capabilities. The company serves customers across the aerospace, defense, energy, motorsport, marine, and other high-performance industries. Cambium Biomaterials, Inc. was founded in 2019 by Simon Waddington and Stephan Herrera. Cambium Biomaterials, Inc. headquarters are located in El Segundo, California.
Keywords
Keywords
Classified
Private
News
Loading...